Mobilized peripheral blood progenitor cells (PBPC) are increasingly used as an alternative to bone marrow for autografting procedures. Currently, cyclophosphamide (CY) followed by granulocyte colony-stimulating factor (G-CSF) or G-CSF alone are the most commonly used PBPC mobilization schedules. In an attempt to investigate whether the use of these two mobilization regimens could result in the collection of functionally different CD34 ؉ cells, we analyzed nucleated cells (NC), CD34 , P р 0.7). This resulted from a mean number of NC that was significantly lower in the CY+G-CSF products than in the G-CSF products (12.4 ؎ 1.7 ؋ 10 9 vs 32 ؎ 5.4 ؋ 10 9 , P р 0.0001) and a mean incidence of CD34 ؉ cells that was significantly higher in the CY؉G-CSF products than in the G-CSF products (2.9 ؎ 0.6% vs 0.9 ؎ 0.2%, P р 0.0018). The mean (؎ s.e.m.) number of CFU-GM collected per apheresis was significantly higher in the CY+G-CSF group than in the G-CSF group (37 ؎ 7 ؋ 10 6 vs 14 ؎ 2 ؋ 10 6 , P р 0.03). Interestingly, CY+G-CSF-mobilized CD34 ؉ cells had a significantly higher plating efficiency than G-CSF-mobilized CD34 ϩ cells (25.5 ؎ 2.9% vs 10.8 ؎ 1.9%, P р 0.0006). In addition, the mean number of LTC-IC was significantly higher in the CY+G-CSF products than in the G-CSF products (6.3 ؎ 1 ؋ 10 6 vs 3.3 ؎ 0.3 ؋ 10 6 , P р 0.05). In conclusion, our data provide evidence that CY؉G-CSF and G-CSF induce the mobilization of CD34 ؉ cells with 
Mobilized peripheral blood progenitor cells (PBPC) are increasingly used as an alternative to bone marrow for autografting procedures. 1 The main advantage of using PBPC is the more rapid hematopoietic reconstitution which is associated with reduced transplant-related mortality and morbidity as well as reduced costs. 2 Chemotherapy and hematopoietic growth factors, either alone or in combination, increase the number of circulating hematopoietic progenitor cells. 3, 4 Recently, CD34 + cells mobilized by granulocyte colony-stimulating factor (G-CSF) following chemotherapy have been demonstrated to be enriched in primitive progenitors, 5 indicating that PBPC mobilization consists of a non-random release of progenitors from the marrow. It is still controversial whether a similar non-random release of CD34 + cells can be achieved with administration of G-CSF alone.
Progenitor cell homing, retention in the marrow and egress into the circulation involve the regulation of adhesive interactions between progenitors and the stromal microenvironment. Such interactions are mediated by cell adhesion molecules as well as ligand-receptor systems, including c-kit receptor and Thy-1. 6, 7 Thus, progenitor cell release is likely to involve the down-regulation of cell adhesion molecules and both the modulation of physiological mechanisms and the activation of non-physiological mechanisms of signal transduction. 6 However, the bio-molecular mechanisms of mobilization are unknown and considerable empiricism remains in designing blood mobilization protocols.
Analysis of mobilized progenitors is mainly based on phenotypic and in vitro cell culture techniques. 8, 9 According to the correlation between circulating CD34 + cells and colony forming cells (CFC), 10 flow cytometric detection of CD34 + cells has been used to estimate mobilized progenitors. However, such a correlation has not been consistently confirmed in leukapheresis products or in the case of growth factor administration. 11, 12 Moreover, different in vitro clonogenic activities displayed by differently mobilized CD34 + cells indicates that phenotypic analysis is a quantitative parameter and does not provide qualitative information concerning the proliferative potential of stem/progenitor cells. 12, 13 The long-term culture initiating cell (LTC-IC) assay, which detects self-renewing progenitors capable of initiating and sustaining hematopoiesis for at least 5 weeks in long-term culture, 14 has been used to detect hematopoietic progenitors both in steady-state and mobilized blood 13, [15] [16] [17] and is considered to be an efficient assay system for measuring the primitive progenitor cell content of mobilized blood. 9, 18 No definitive comparison has so far been provided on the mobilization potential of different schedules in terms of both clonogenic and primitive progenitors. In an attempt to investigate whether the use of different mobilization regimens could result in functional differences of CD34 + cells, we analyzed nucleated cells (NC), CD34
+ cells, colony-forming cells and LTC-IC in 52 leukaphereses from 26 patients with lymphoid malignancies, mobilized either by cyclophosphamide (CY) plus G-CSF or G-CSF alone.
Patients and methods

Patients, mobilization regimens and harvesting criteria
The main clinical characteristics of the patients included in this study are summarized in Table 1 . Twenty-six patients Table 1 Characteristics of patients at the time of mobilization (15 males, 11 females) with a diagnosis of Hodgkin's disease (n = 3), non-Hodgkin's lymphoma (n = 10) and multiple myeloma (n = 13) underwent PBPC mobilization with either G-CSF (5 g/kg/day until completion of leukaphereses) after cyclophosphamide (4 or 7 g/m 2 ) (n = 16) or G-CSF alone (10 g/kg/day until completion of leukaphereses) (n = 10). PBPC collections were started when circulating CD34 + cells were у20/l in the CY+G-CSF group and on day +5 of G-CSF administration in patients mobilized with G-CSF alone. In both groups, leukaphereses were continued until an average number of 7 x 10 6 cD34 + cells/kg body weight was collected. Apheretic procedures were performed using a Cobe-Spectra continuous flow cell separator (Cobe Laboratories, Lakewood, CO, USA). 
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CFU-Mix, BFU-E and CFU-GM assay
The assay for multipotent CFU-Mix, erythroid BFU-E, and granulocyte-macrophage CFU-GM was carried out as described elsewhere. 19 Briefly, 1-5 x 10 4 nucleated cells were plated in 35-mm Petri dishes in 1 ml aliquots of IMDM containing 30% FBS (Stem Cell Technologies, Vancouver, Canada), 10 -4 M 2-mercaptoethanol (Gibco, Grand Island, NY, USA) and 1.1% (w/v) methylcellulose. Since the percentage of CD34 + cells was significantly higher in the CY+G-CSF products than in the G-CSF products (2.9 Ϯ 0.6% vs 0.9 Ϯ 0.2%, P р 0.0018), in order to plate comparable numbers of CD34 + cells the absolute number of nucleated cells plated per dish was adjusted according to the percentage of CD34 + cells in each apheresis. Cultures were stimulated with interleukin-3 (10 ng/ml; Sandoz, Basel, Switzerland), granulocyte colony-stimulating factor (10 ng/ml; Amgen, Thousand Oaks, CA, USA), granulocyte-macrophage colony-stimulating factor (10 ng/ml; Sandoz) and erythropoietin (3 U/ml; Amgen). Progenitor cell growth was evaluated after 14-18 days of incubation (37°C, 5% CO 2 ) in a humidified atmosphere. Four dishes were set up for each individual data point per experiment. CFU-Mix, BFU-E and CFU-GM were scored from the same dish according to previously published criteria. 19 
LTC-IC assay
The long-term culture-initiating cell (LTC-IC) assay was performed according to Sutherland et al. 20 Briefly, test cell (5 x 10 6 nucleated cells) suspension was seeded into cultures containing a feeder layer of irradiated (8000 cGy) murine M2-10B4 cells (3 x 10 4 /cm 2 , kindly provided by Dr C Eaves) engineered by retroviral gene transfer to produce human IL-3 and human G-CSF. 21 Test cells were resuspended in complete medium consisting of alpha-medium (Gibco) supplemented with fetal bovine serum (12.5%), horse serum (12.5%), L-glutamine (2 mM), 2-mercaptoethanol (10 −4 M), inositol (0.2 mM), folic acid (20 M) and freshly dissolved hydrocortisone (10 −6 M). Cultures were fed weekly by replacement of half of the growth medium containing half of the nonadherent cells with fresh complete medium. After 5 weeks in culture, nonadherent cells and adherent cells harvested by trypsinization were pooled, washed, and assayed together for clonogenic cells in standard methylcellulose cultures at an appropriate concentration. The total number of clonogenic cells (ie CFU-Mix plus BFU-E plus CFU-GM) present in 5-week-old LTC provides a relative measure of the number of LTC-IC originally present in the test suspension. 15 Absolute LTC-IC values were calculated by dividing the total number of clonogenic cells by 4, which is the average output of clonogenic cells per LTC-IC, according to limiting dilution analysis studies reported by others. 16 
Statistical analysis
Four plates were scored for each data point per experiment and the results were expressed as the mean Ϯ 1 standard error of the mean (Ϯ s.e.m.). Statistical analysis was performed with the statistical package Statview (BrainPower, Calabasas, CA, USA) run on a Macintosh Performa 6300 personal computer (Apple Computer). The two-tailed Student's t-test for unpaired data was used to test for significance of differences between samples. Correlations were determined using the least square linear regression analysis.
Results
Thirty-four apheresis products from 16 patients mobilized with CY+G-CSF and 18 products from 10 patients mobilized with G-CSF alone were studied. The main clinical characteristics of the two groups of patients at the time of mobilization are reported in Table 1 . There were no major differences between the two groups in terms of age, diagnosis, disease status, time from diagnosis and time from last chemotherapy. Number of previous chemotherapy cycles was significantly higher in the CY+G-CSF group (median 7, range 0-13) than in the G-CSF group (median 2, range 0-6) (P р 0.04).
Nucleated cells and CD34 + cells in blood and leukapheresis
Nucleated cells (NC) and CD34
+ cells in peripheral blood and leukapheresis products are summarized in Table 2 .
Values of CD34
+ cells per l were comparable in the two groups and resulted from significantly lower mean (Ϯ s.e.m.) values of white blood cells (WBC) in the CY+G-CSF group than in the G-CSF group (12 Ϯ 1.9 x 10 9 /l vs 35 Ϯ 3 x 10 9 /l, P р 0.0001) and higher percentages of circulating CD34
+ cells in the CY+G-CSF group than in the G-CSF group (1.3 Ϯ 0.3% vs 0.3 Ϯ 0.1%, P р 0.0063). According to study design, leukaphereses were carried out until an average number of 7 x 10 6 CD34 + cells per kg body weight was collected. As shown in , P = 0.7). This finding resulted from a mean number of NC that was significantly lower in the CY+G-CSF products than in the G-CSF products (12.4 Ϯ 1.7 x 10 9 vs 32 Ϯ 5.4 x 10 9
, P р 0.0001) and a mean incidence of CD34 + cells that was significantly higher in the CY+G-CSF products than in the G-CSF products (2.9 Ϯ 0.6% vs 0.9 Ϯ 0.2%, P р 0.0018) ( Table 2) .
Committed progenitors
Values of committed progenitors (CFU-Mix, BFU-E, CFU-GM) collected in leukapheresis products are summarized in Table 3 . Mean (Ϯ s.e.m.) CFU-Mix concentration per 5 x 10 4 NC was not significantly higher in the CY+G-CSF group than in the G-CSF group (4.5 Ϯ 0.9 vs 2 Ϯ 0.6, P = 0.06). Mean BFU-E and CFU-GM per 5 x 10 4 NC were significantly higher in the CY+G-CSF group than in the G-CSF group (43 Ϯ 7.5 vs 19 Ϯ 4.5 (P р 0.03) and 144 Ϯ 20 vs 30 Ϯ 5.4 (P р 0.0001)). The yields of CFUMix and BFU-E, both per apheresis and total per kg body weight, were higher in the CY+G-CSF group than in the G-CSF group, but the difference was not statistically significant. Mean yields of CFU-GM per apheresis and per kg body weight were significantly higher in the CY+G-CSF group than in the G-CSF group (37 Ϯ 7 x 10 
Primitive progenitors
In 22 leukapheresis products obtained by the CY+G-CSF regimen and in 13 products obtained by the G-CSF regimen, the growth of primitive LTC-IC progenitors could be investigated. As shown in Table 4 , mean (Ϯ s.e.m.) LTC-IC concentration per 2 x 10 6 nucleated cells from leukapheresis products was significantly higher in the CY+G-CSF group than in the G-CSF group (346 Ϯ 73 vs 27 Ϯ 7, P р 0.002). Concentrations of LTC-IC detected in each leukapheresis on a daily basis are reported in Figure 2 . In both mobilization groups, LTC-IC concentration did not significantly change over time. The mean number of LTC-IC collected per apheresis was significantly higher in the CY+G-CSF products than in the G-CSF products (6.3 Ϯ 1 x 10 6 vs 3.3 Ϯ 0.3 x 10 6 , P р 0.05).
Correlations between CD34 + cells, CFU and LTC-IC
As reported in Figures 3 and 4 , CD34 + cell concentration was correlated to CFC and LTC-IC values. In the CY+G-CSF group, a significant correlation was found between absolute numbers of CD34 + cells per 5 x 10 4 nucleated cells and the corresponding CFC values (R = 0.68, P р 0.0001) (Figure 3a) . A similar finding was also observed when 565 Table 4 LTC-IC in leukapheresis products 
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+ cells were correlated with the different subtypes of committed progenitors, ie CFU-Mix, BFU-E and CFU-GM (data not shown). A weak correlation was also found between numbers of CD34 + cells and the corresponding LTC-IC values (R = 0.47, P р 0.027), indicating a relationship between the level of CD34 + cells collected and the primitive progenitors harvested (Figure 4a ). In the G-CSF group, no significant correlation was found between CD34 + and either CFC (Figure 3b ) or LTC-IC (Figure 4b) values.
Discussion
The increasing use of mobilized progenitors for autologous transplantation has been paralleled by a number of studies showing that different mobilization schedules can be used to collect cells with hematopoietic reconstituting ability. [1] [2] [3] 5, 12, 13, 22 Both chemotherapy or growth factors used alone expand the pool of circulating progenitors and, when combined, exert a significantly higher effect.
3,4 Fol- lowing CY+G-CSF administration, circulating CD34 + cells and committed progenitors initially decrease to undetectable levels, while reappearing together with the more primitive LTC-IC at the time of leukocyte recovery. 16, 23 Similarly, G-CSF mobilizes into the circulation primitive progenitors capable of self-renewal along with committed progenitors. 17 Although primitive and committed progenitors can be detected in the blood following mobilization with a number of different regimens, it is still unclear whether or not qualitative and/or quantitative differences exist among different mobilization regimens in terms of hematopoietic mobilization potential. By comparing the mobilizing effects of CY+G-CSF with G-CSF alone in patients undergoing an average collection of 7 x 10 6 CD34 + cells per kg of body weight, we demonstrate that CY+G-CSF mobilizes significantly higher amounts of primitive and committed progenitors despite collection of comparable numbers of CD34 + cells. This finding, which is in agreement with previously reported data, 24 was achieved by comparing two populations of patients significantly different in terms of premobilization chemotherapy, with the CY+G-CSF group having received a significantly higher number of chemotherapy cycles prior to mobilization than the G-CSF group (Table 1) . Progenitor cell mobilization is known to be negatively affected by the number of chemotherapy cycles before PBPC mobilization, pelvic radiotherapy and age. 22, 25 The higher mobilization potency of CY+G-CSF observed in a patient population that had been pre-treated with a significantly higher number of chemotherapy cycles as compared to patients mobilized with G-CSF alone, strongly suggests that the priming regimen by itself was determinant in the recruitment of higher amounts of primitive and committed progenitors. Differences in pre-mobilization treatment were only likely to determine the strong inter-patient variability observed in hematopoietic progenitor cell harvests. Differences in distribution by disease between the two groups of patients might account for the different mobilization potency of CY+G-CSF vs G-CSF alone. However, a preliminary analysis involving only multiple myeloma patients (seven mobilized with CY+G-CSF and six with G-CSF alone) demonstrated mobilization patterns equal to those observed by comparing the two populations of patients reported here.
Differences in the quantitative recruitment of hematopoietic progenitors in the bloodstream achieved by different mobilization schedules might be dependent on the relative frequency of CD34 + subpopulations that are not clonogenic in short-term culture assay systems, such as lymphoid progenitors as well as primitive progenitors and stem cells. 12, 13 We found that CD34
+ cells from the G-CSF group had a significantly lower plating efficiency than CY+G-CSF mobilized CD34 + cells. This finding associated with the significantly lower numbers of LTC-IC detected in the G-CSFmobilized products suggests that the lower clonogenicity of CD34 + cells observed in G-CSF-mobilized patients was likely to be due to the mobilization of mature CD34 + cells which are not detected in the CFU-Mix assay. Moreover, poor correlations between CD34 + cells, CFC and LTC-IC indicate that G-CSF-induced mobilization of CD34 + cells should be viewed as a random process depending on the exit of progenitor and precursor cells from the marrow. In agreement with previous studies suggesting that chemotherapy plus growth factors result in a non-random release of progenitors into the bloodstream, 5 a large proportion of primitive LTC-IC was mobilized with the CY+G-CSF schedule which resulted in significant correlations between CD34 + cells, CFC and LTC-IC. 13 A previous report investigating newly diagnosed breast cancer patients receiving repeated cycles of dose escalating FAC chemotherapy has demonstrated that G-CSF alone is more effective than chemotherapy plus G-CSF in mobilizing LTC-IC. 26 The apparent discrepancies between these observations and ours may be related to different patient populations (solid tumor vs hematologic malignancies) as well as different chemotherapy regimens used for PBPC mobilization.
The lower clonogenic activity of G-CSF-mobilized CD34
+ cells could hypothetically be dependent on differences in the cell composition of apheretic samples mobilized by CY+G-CSF and G-CSF alone. In fact, low numbers of CD34
+ cells associated with high numbers of mature and accessory cells secreting inhibitors of cell proliferation might have down-regulated the growth of G-CSF-mobilized progenitors. To prevent, at least in part, the negative effects of cell composition on progenitor cell growth, we set up methylcellulose cultures with similar numbers of CD34 + cells, ie the number of plated cells was adjusted according to the percentage of CD34 + cells detected in each apheretic sample. In addition, the number of plated cells was always within the range of cell concentrations which in preliminary experiments had been shown to allow a linear correlation between CD34
+ cells and colony-forming cells. However, the role of accessory cells negatively affecting colony formation will require additional experiments using CD34 enriched cell fractions.
Mechanisms underlying progenitor cell release from the marrow into the bloodstream involve alterations of the physiological adhesive interactions between progenitor cells and marrow stroma. 6, 9 Growth factors have been shown to modulate progenitor cell adhesion either by regulating the expression and/or activation state of cell adhesion molecules, or influencing extra-cellular matrix biosynthesis and degradation, or modulating ligand-receptor systems that are able to support progenitor-stroma cell adhesion. 6, 7 Cytotoxic agents such as CY damage the marrow-endothelial cell barrier and facilitate the release of hematopoietic cells into the bloodstream. 27 Thus, a variety of perturbations result in a transient release of progenitors into the peripheral circulation. Qualitative differences of CD34 + cells mobilized by CY+G-CSF and G-CSF are likely to be due to combined and partially overlapping effects of CY and G-CSF and may reflect, at the molecular level, a different modulation of factors implicated in the mobilization mechanism. In addition, marrow aplasia following high-dose cyclophosphamide might have a role in the enrichment of clonogenic progenitors and LTC-IC by inducing both the selective mobilization of primitive CD34 + cells and their synchronization in a cell cycle phase that makes them highly responsive to in vitro stimulation by growth factors. 28 Mobilized PBPC have been found to have similar longterm repopulating abilities to steady state marrow 29 and support a rapid and complete hematopoietic reconstitution in the allogeneic setting. 30 Autologous PBPC also support complete engraftment after myeloablative therapy. 31 However, the origin of hematopoietic recovery in autografted patients may be controversial due to the lack of a satisfactory assay for human stem cells and the difficulty of determining the contribution of reinfused autologous cells to hematopoietic recovery. Quantitation of long-term repopulating stem cells in the blood after treatment with mobilizing agents is of considerable interest. In a murine model, a greater increase of primitive progenitors after CY+G-CSF than after G-CSF mobilization has been demonstrated. 32 In the human setting, our results provide evidence that, although detectable levels of LTC-IC are reached in PBPC collections following both mobilization schedules, the CY+G-CSF regimen is much more effective than the G-CSF method in harvesting primitive progenitors in terms of LTC-IC.
The outcome of autografting substantially depends on engraftment of pluripotent hematopoietic stem cells in the marrow microenvironment and the capability of stem cells of homing to the marrow and docking at specific sites. 33 Despite recent evidence demonstrating that the LTC-IC assay detects a class of primitive stem cells with phenotype characteristics of transplantable murine in vivo repopulating cells 34 and self-renewal potential, 14 the role of primitive LTC-IC in promoting hematopoietic recovery following autografting as well as the dose of these progenitors which is required for a prompt and durable engraftment is still a matter of controversy. Murine studies in which isoenzyme analysis and retroviral gene marking of hematopoietic cells have been used to track the fate of stem cells support the existence of distinct subsets of stem cells which may be responsible for short-term and long-term engraftment after stem cell transplantation. 35, 36 In human subjects there is no clear evidence for the separation of distinct subsets of cells with differing repopulating potentials. A functional heterogeneity of transplantation potential of human stem cells can be argued from recipients of mobilized peripheral blood transplants who have a rapid hematopoietic reconstitution suggesting either that mobilized peripheral blood is enriched for short-term repopulating stem cells or a substantial contribution of CFU-GM in the early phase of engraftment. 22 By using a homogeneous population of primitive human hematopoietic cells, in vitro evidence has been provided suggesting the existence of a mechanism that can provide both short-term and long-term hematopoietic repopulation. 37 A marked LTC-IC reduction in patients with acute myelogenous leukemia has recently been demonstrated to be a biologically relevant factor conditioning prolonged pancytopenia and increased transplant-related mortality following autografting. 38 Although there is no clear quantitative evidence of the dose of LTC-IC which should be reinfused in order to obtain a sustained engraftment on a long-term basis, our data imply that every mobilization regimen should be carefully evaluated on a pre-clinical basis before being applied in vivo for autografting purposes. Although a sufficient number of committed progenitors might be collected with a number of different mobilization regimens, the reconstitutive potential of such regimens might be compromised by the use of some chemotherapeutic agents known to significantly damage marrow stroma or LTC-IC. 38 In conclusion, our data show that CD34
+ cells mobilized by CY+G-CSF have higher clonogenic activity and primitive progenitor cell content than CD34
+ cells mobilized by G-CSF. These functional differences seem to be dependent on the mobilization schedules. Since mobilized PBPC containing large number of progenitors lead to safer transplantation, our results may have relevant implications for planning mobilization strategies and suggest a careful pre-clinical evaluation of the hematopoietic mobilization potential of different mobilization regimens.
